To date, the only definitive treatment available for acute or chronic end-stage liver disease is liver transplantation. Due to a lack of donor livers, over the past decade, major advancements have been made in the research field broadly termed “regenerative Hepatology”. These include breakthroughs in stem cell research and in the development of advanced biotechnologies/biomaterials.
The aim of the EASL Consortium for Regenerative Hepatology is the delivery of bioengineered tissues and associated biotechnologies for regenerative Hepatology.
The activity of the EASL Consortium for Regenerative Hepatology will be focused on three main research programs.